February 10, 2009

Ireland's Elan trims losses as MS drug sales surge

Irish biotechnology company Elan Corp. said Tuesday its losses narrowed sharply in 2008 as sales surged, driven by its top drug, the multiple sclerosis treatment Tysabri.

More: continued here

Filed under Alzheimers by GR

Permalink • Print • Email • Comment

Trackback uri

http://www.alzheimers.wahwarriors.com/alzheimers/irelands-elan-trims-losses-as-ms-drug-sales-surge/trackback

Track this entry

BlogPulse

Technorati Cosmos

Related Entries

Irish drugmaker Elan records 4th-quarter loss, sees 2010 rebound amid strong Tysabri sales
Elan, Biogen Plunge After Patients Taking Tysabri Develop Brain Infections
Drugs for treatment of Alzheimer's, Multiple Sclerosis and Parkinsons diseases - market growth and forecasts
Antipsychotic drug binding in the substantia nigra: An examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia
New Therapeutic Area Study Assesses Market Forecast for Neurodegenerative Drugs Through 2013: Cutting Edge Information Report Analyzes Alzheimer's Disease, Multiple Sclerosis, and Parkinson's Disease Drug Portfolios and Market Prospects

You must be logged in to post a comment.

February 10, 2009

Ireland's Elan trims losses as MS drug sales surge

Trackback uri

Track this entry

Related Entries

Leave a Comment

Recent Posts